Dr. Monleón received his doctorate in Chemistry from the University of Valencia.
He has conducted research into the biomedical applications of Nuclear Magnetic Resonance (NMR) for more than 20 years. After his doctorate, he took a 3-year postdoctoral post at the center for Advanced Biotechnology and Medicine at Rutgers University to develop NMR applications for elucidating protein structures. After returning from his postdoctoral stay, he focused his research on the applications of NMR in metabolism research for diagnostic purposes. In 2004 he was selected as the Scientific Manager of the eTUMOUR consortium financed by the 6th European Union Framework Program (7.5 million euros, 21 European Institutions). He is the Principal Investigator of the University Clinical Hospital Research Foundation in Valencia (FIHCUV; Fundación de Investigación del Hospital Clínico Universitario de Valencia) Metabolomic Group and has been on a Ramón y Cajal contract from the Science and Innovation Ministry since 2006; he has been an Associate Professor in the Pathology Department at the University of Valencia since 2008.
His research and teaching career was recognized by the National Evaluation and Foresight Agency (ANEP; Agencia Nacional de Evaluación y Prospectiva) with an outstanding research path certification in 2011, as well as by the National Agency of Quality and Accreditation Evaluation (ANECA; Agencia Nacional de Evaluación de la Calidad y Acreditación) with an accreditation as an Associate Professor in 2012. He has obtained grants, awards, accreditations and recognitions from several institutions such as the Ministry of Education and Science, the Generalitat Valenciana (Valencian regional government) Regional Education Department, the International University Menéndez y Pelayo, the Ministry of Foreign Affairs, the Spanish Society of Optics, the European Society for Magnetic Resonance in Medicine and Biology, and the Robert-Wood Johnson Hospital in New Jersey, among others. He has taught in several national and international universities, among which are the Rutgers University, the University of Oulu, the Catholic University of Louvain, and the Norwegian University of Science and Technology in Trondheim. He has published more than 80 research articles in high impact-factor journals registered on the Journal Citation Reports (JCR) of the ISI web including Hepatology, Cancer Research, the Journal of the American College of Cardiology, Antioxidant and Redox Signaling, the Journal of Biological Chemistry, and the Journal of Molecular Biology. He has participated in several regional research projects, in the national R&D and innovation (I+D+I) plan, in the National Science Foundation (NSF) and the National Institutes of Health (NIH) in the USA, and in the FP6 and FP7 European Union grants, as the Principal Investigator on some of them. According to ResearchGate, his scientific contribution is higher than 92.5% of all the researchers in the community.
His research focuses on studying metabolic profiles in order to help and support the diagnosis, characterization, and selection of therapies in different diseases. The lines of research of his group are focused on studying metabolism from the point of view of reagents and products. Metabolism includes the set of chemical conversions that occurs in cells in order to sustain life. Although the regulatory enzymes in these reactions have been characterized and extensively studied, there is still a lack of knowledge about the relationships among different reagents and products (metabolites) and pathological states. His group’s research focuses on studying this relationship along two broad research lines: 1) tumor metabolism and angiogenesis, 2) and metabolic profiles in cardiovascular disease. His studies continue the search of disease metabolic profiles in patients and experimental models (cells and animals) to relate these profiles with processes and mechanisms, and finally, trying to better stratify and risk-assess patients based on these findings as well as providing better prognostic and therapy response predictions. To do this the group uses complex mathematical chemometric analysis tools which allow them to incorporate all of the data obtained (clinical, metabolic, genetic, etc.).
• Management of differential metabolic profiles associated with microalbuminuria in the general population.
• Development of risk stratification methodology by statistical combination of genetic polymorphisms and metabolic profiles.
• Management of differential metabolic tumor recurrence profiles in meningioma biopsies.
• Management of differential gene expression profiles in recurrent meningioma tumor biopsies.